MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Pathophysiological mechanisms of bone mass loss for osteoporosis prevalence in Parkinson’s disease

L.A. Leandro, H.A.G. Teive (Curitiba, Brazil)

Meeting: 2016 International Congress

Abstract Number: 884

Keywords: Aging, Parkinsonism, Posture, Rehabilitation

Session Information

Date: Tuesday, June 21, 2016

Session Title: Parkinson's disease: Pathophysiology

Session Time: 12:30pm-2:00pm

Location: Exhibit Hall located in Hall B, Level 2

Objective: Quantify the impact of osteoporosis in Parkinson’s disease to know factors that caused bone loss.

Background: Parkinson´s disease (PD) and osteoporosis are two conditions with high prevalence in older people. A multifactorial etiophatogenesis characterized by an abnormal reduction of the bone mass, become this population more fragile and exposed to the risk of falls and fractures. In addition, postural instability is another negative factor.

Methods: A Medline search was performed for articles published between December 2010 and December 2015, using these keywords: ‘bone mineral density’ (BMD), ‘bone metabolism’, ‘osteoporosis’, ‘elderly’ and ‘Parkinson’s disease’.

Results: PD patients have a lower bone mineral density (BMD) compared with patients with the same age and without the disease. The bone loss in Parkinson’s disease is multifactorial, the result of immobility, decreased muscle strength and low body weight. A deficiency of vitamin D is also important, not only because reduces BMD, but also because cell function in the substantia nigra depends on vitamin D. A few studies have demonstrated that treatment with bisphosphonates, vitamin D and calcium can increase BMD and reduce fractures in PD patients with PD as well as hospitalizations and premature death.

Conclusions: The multifactorial nature is the main feature of bone loss in PD. Frequent assessments of the degree of osteoporosis defines better therapeutic strategies and Quality of Life.

To cite this abstract in AMA style:

L.A. Leandro, H.A.G. Teive. Pathophysiological mechanisms of bone mass loss for osteoporosis prevalence in Parkinson’s disease [abstract]. Mov Disord. 2016; 31 (suppl 2). https://www.mdsabstracts.org/abstract/pathophysiological-mechanisms-of-bone-mass-loss-for-osteoporosis-prevalence-in-parkinsons-disease/. Accessed September 5, 2025.
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2016 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/pathophysiological-mechanisms-of-bone-mass-loss-for-osteoporosis-prevalence-in-parkinsons-disease/

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • An atypical and interesting feature of Parkinson´s disease
  • An Apparent Cluster of Parkinson's Disease (PD) in a Golf Community
  • #23812 (not found)
  • Approaching Health Care Shaped by Generational Expectations (The AGE Study): Generational Perspective Related to Time
  • Application of the “5-2-1” Screening Criteria in Advanced Parkinson’s Disease Patients Treated with Levodopa-Carbidopa Intestinal Gel: Interim Analysis from the DUOGLOBE Study
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • Effect of Ketone Ester Supplementation on Motor and Non-Motor symptoms in Parkinson's Disease
  • An atypical and interesting feature of Parkinson´s disease
  • Patients with Essential Tremor Live Longer than their Relatives
  • DaTscan in clinical evaluation of Multiple System Atrophy
  • Decision-making process for opicapone’s bedtime regimen
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley